Anti–platelet factor 4 testing for heparin-induced thrombocytopenia: Assessing the indication for its use for quality improvement as a patient safety measure
Most HIT testing was inconsistent with guideline recommendations of the American Society of Hematology. Overtesting may lead to unnecessary anticoagulation, and undertreatment may have occurred in high-risk cases. These findings underscore the need for improved implementation of 4T-based decision tools to guide HIT evaluation and treatment.
Authors
- Lydia Howard (ORCID: https://orcid.org/0000-0003-2283-5183)
- Vathany Sriganeshan (ORCID: https://orcid.org/0000-0002-5437-947X)
- Esha Vallabhaneni
- Kei Shing Oh
- Ruben Delgado
- Hisham F. Bahmad (ORCID: https://orcid.org/0000-0003-3799-2595)
- Richard R. Pacheco (ORCID: https://orcid.org/0000-0002-9919-7290)
- Roshanak Azimi
- Sarah Alghamdi (ORCID: https://orcid.org/0000-0003-0264-2245)
- Robert Poppiti (ORCID: https://orcid.org/0000-0003-2561-2583)
- Lina Gomez
Institutions
- Florida International University (US)
- Mount Sinai Medical Center (US)
- Albany Medical Center Hospital (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1093/ajcp/aqaf102
- Primary Topic
- Heparin-Induced Thrombocytopenia and Thrombosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00